Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.
Gui G, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, Auletta JJ, El Chaer F, Chen EC, Chen YB, Corner A, Devine SM, Iyer SG, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Dillon LW, Hourigan CS. Gui G, et al. Among authors: corner a. Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02447-4. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39506075
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.
Gui G, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, Auletta JJ, El Chaer F, Chen EC, Chen YB, Corner A, Devine SM, Iyer SG, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Dillon LW, Hourigan CS. Gui G, et al. Among authors: corner a. Bone Marrow Transplant. 2024 Oct 25. doi: 10.1038/s41409-024-02449-2. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39455897
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia.
Hegde PS, Andrew G, Gui G, Ravindra N, Mukherjee D, Wong ZC, Auletta JJ, El Chaer F, Corner A, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Dillon LW, Hourigan CS. Hegde PS, et al. Among authors: corner a. Bone Marrow Transplant. 2024 Oct 18. doi: 10.1038/s41409-024-02444-7. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39424958 No abstract available.
Recommendations from the AML molecular MRD expert advisory board.
Scott S, Devonshire A, Dillon R, Thiede C, Cross NCP, White HE, Lo Cascio L, Mokretar K, Potter N, Hourigan CS, Radich J, Corner A, Laloux V, Halliday G, Dilks D, Morrison T, Gilmour K, Cartwright A, Whitby L. Scott S, et al. Among authors: corner a. Leukemia. 2024 Jul;38(7):1638-1641. doi: 10.1038/s41375-024-02275-x. Epub 2024 May 23. Leukemia. 2024. PMID: 38783160 Free PMC article. No abstract available.
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
Ravindra N, Dillon LW, Gui G, Smith M, Gondek LP, Jones RJ, Corner A, Hourigan CS, Ambinder AJ. Ravindra N, et al. Among authors: corner a. Bone Marrow Transplant. 2024 Mar;59(3):428-430. doi: 10.1038/s41409-023-02189-9. Epub 2024 Jan 5. Bone Marrow Transplant. 2024. PMID: 38182672 No abstract available.
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
Ravindra N, Dillon LW, Gui G, Smith M, Gondek LP, Jones RJ, Corner A, Hourigan CS, Ambinder AJ. Ravindra N, et al. Among authors: corner a. medRxiv [Preprint]. 2023 Aug 21:2023.08.14.23294087. doi: 10.1101/2023.08.14.23294087. medRxiv. 2023. Update in: Bone Marrow Transplant. 2024 Mar;59(3):428-430. doi: 10.1038/s41409-023-02189-9 PMID: 37662423 Free PMC article. Updated. Preprint.
Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia.
Gui G, Dillon LW, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, Auletta J, El Chaer F, Chen E, Chen YB, Corner A, Devine SM, Iyer S, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Spellman SR, Zeger SL, Page KM, Hourigan CS. Gui G, et al. Among authors: corner a. medRxiv [Preprint]. 2023 Aug 1:2023.07.28.23293166. doi: 10.1101/2023.07.28.23293166. medRxiv. 2023. Update in: JAMA Oncol. 2024 Aug 1;10(8):1104-1110. doi: 10.1001/jamaoncol.2024.0985 PMID: 37577695 Free PMC article. Updated. Preprint.
107 results